Directive transparence : information réglementée

26/01/2023 08:00

Arix Bioscience PLC (ARIX)
Board Change

26-Jan-2023 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

Board Change

London, 26 January 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, today announces Dr Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.

Peregrine Moncreiffe, Chairman of Arix, commented: “On behalf of the Board, I would like to thank Benny for the support he has shown to the Company since joining the Board last year and wish him well in his future endeavours.”



For more information, please contact:


Arix Bioscience plc

+44 (0)20 7290 1050



Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446




About Arix Bioscience plc


Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.


We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com


ISIN: GB00BD045071
Category Code: BOA
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 218423
EQS News ID: 1543761

End of Announcement EQS News Service